Q1 Earnings Estimate for CRBU Issued By HC Wainwright

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for Caribou Biosciences in a report released on Wednesday, March 19th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million.

Several other equities research analysts have also recently commented on the company. Bank of America cut their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Citigroup dropped their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Stock Performance

NASDAQ:CRBU opened at $1.04 on Friday. Caribou Biosciences has a one year low of $0.95 and a one year high of $5.62. The stock has a market cap of $96.73 million, a PE ratio of -0.63 and a beta of 2.34. The stock has a 50 day moving average price of $1.29 and a 200 day moving average price of $1.74.

Institutional Trading of Caribou Biosciences

Several hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its position in shares of Caribou Biosciences by 475.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock valued at $3,969,000 after acquiring an additional 2,062,563 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Caribou Biosciences during the fourth quarter worth about $1,921,000. Schonfeld Strategic Advisors LLC grew its holdings in shares of Caribou Biosciences by 28.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company’s stock worth $3,360,000 after buying an additional 467,738 shares in the last quarter. Two Sigma Advisers LP grew its holdings in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company’s stock valued at $2,338,000 after buying an additional 416,600 shares during the period. Finally, Ameriprise Financial Inc. purchased a new stake in Caribou Biosciences in the 4th quarter valued at about $649,000. 77.51% of the stock is owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.